根治性前列腺切除术中神经血管结构旁冷冻切片检查(NeuroSAFE):系统综述与Meta分析
该系统综述与Meta分析纳入14项研究、9个独立患者人群,共15 446例患者中7 505例接受NeuroSAFE。累积分析显示NeuroSAFE组切缘阳性风险显著更低(OR 0.68,95%CI 0.51-0.91,I²=79%),2年生化复发无差异(OR 0.79,95%CI 0.53-1.18,I²=63%)。所有设对照组的研究中NeuroSAFE组勃起功能率更高,控尿率无显著差异;证据等级弱,随机试验结果待出。
要点
- NeuroSAFE组切缘阳性风险显著低于对照组(OR 0.68,95%CI 0.51-0.91,I²=79%)。
- 2年生化复发无显著差异(OR 0.79,95%CI 0.53-1.18,I²=63%)。
- 所有设对照组的研究中NeuroSAFE组勃起功能率更高,控尿率无显著差异。
核心结论
- NeuroSAFE可提高保留神经手术率、降低切缘阳性率、生化复发率相似且不良事件率低,提示其肿瘤学安全。
- NeuroSAFE似乎改善功能结局尤其是勃起功能,但随机试验结果待出。
- 证据等级为弱。
研究设计与样本
- 系统检索Medline、Embase和Web of Science数据库截至2024年7月。
- 纳入接受根治性前列腺切除术的PCa患者并报告肿瘤学和/或功能结局的研究。
- 共分析14项研究、9个独立患者人群,15 446例患者中7 505例接受NeuroSAFE。
- 采用Review Manager软件以随机效应模型对肿瘤学结局进行累积分析,并对术式和功能结局进行叙述性分析。
主要发现
- 所有研究中NeuroSAFE组保留神经手术数量均高于对照组。
- 累积分析显示NeuroSAFE组切缘阳性风险显著更低(OR 0.68,95%CI 0.51-0.91,I²=79%)。
- 2年生化复发无差异(OR 0.79,95%CI 0.53-1.18,I²=63%)。
- 所有设对照组的研究中NeuroSAFE组勃起功能率更高,无研究报告控尿率有显著差异。
- 不良事件罕见。
临床怎么用
- 作者认为NeuroSAFE提高保留神经手术率、降低切缘阳性率、生化复发率相似且不良事件率低,提示其肿瘤学安全。
- 作者认为NeuroSAFE似乎改善功能结局尤其是勃起功能,但随机试验结果待出。
局限性
- 研究缺乏随机化导致选择偏倚。
- 总体偏倚风险判断从低到严重不等。
- 证据等级为弱。
- 勃起功能影响似乎有前景但需进一步研究。
- 随机试验结果待出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: A standardized intraoperative frozen section analysis of the prostate resection margin adjacent to the neurovascular bundle according to the NeuroSAFE technique is performed to maximize nerve sparing during radical prostatectomy (RP) for prostate cancer (PCa). The aim of this review was to analyze oncological and functional outcomes of NeuroSAFE. METHODS: A systematic search of the Medline, Embase, and Web of Science databases until July 2024 was performed. Studies were eligible if these included men undergoing RP with NeuroSAFE for PCa, and reported on oncological and/or functional outcomes. A cumulative analysis with random-effect models for oncological outcomes was conducted using Review Manager software, together with a narrative analysis of the procedure and functional outcomes. KEY FINDINGS AND LIMITATIONS: We analyzed 14 studies with nine distinct patient populations; 7505 out of 15 446 patients underwent NeuroSAFE. The number of nerve-sparing procedures was higher for patients with NeuroSAFE than for controls in all studies. Cumulative analyses showed a statistically significantly lower risk of positive surgical margins (PSMs) in favor of NeuroSAFE (odds ratio [OR] 0.68, 95% confidence interval [CI] 0.51-0.91, I2 = 79%) and no difference in 2-yr biochemical recurrence (BCR; OR 0.79, 95% CI 0.53-1.18, I2 = 63%). All studies with control groups showed higher potency rates in the NeuroSAFE group; none reported significant difference in continence rates. Adverse events were scarce. Limitations of the studies include a lack of randomization resulting in a selection bias; the overall risk of bias judgment ranged from low to serious. CONCLUSIONS AND CLINICAL IMPLICATIONS: We present the first systematic review on NeuroSAFE during RP. The level of evidence is weak. The increased rate of nerve-sparing surgery, reduced PSMs, similar BCR, and low adverse event rates imply that NeuroSAFE is an oncologically safe technique. NeuroSAFE seems to improve functional outcomes, especially potency, but results of randomized trials are awaited. PATIENT SUMMARY: We know that for patients with prostate cancer who undergo an operation to remove the prostate, sparing the nerve bundles next to each side of the prostate improves continence and erectile function. In this literature review, we evaluated a technique (NeuroSAFE) that aids surgeons in deciding whether they can spare these nerve bundles safely while still operating radically, for example, remove all cancer. We found that the technique is oncologically safe. Furthermore, the impact on potency appears promising but needs further study.
引用
- Kroon LJ, van der Slot MA, van den Bergh RCN, et al. Neurovascular Structure-adjacent Frozen-section Examination (NeuroSAFE) During Radical Prostatectomy: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2024. PMID: 39730246. doi:10.1016/j.euo.2024.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。